This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Biosimilar Eculizumab, Biosimilar Eculizumab (Amgen), ABP959, ABP 959, Biosimilar Soliris
Description: ABP-959 is a biosimilar version of Soliris (eculizumab) under development by Amgen.
Amgen and Laboratorio Quimico Farmaceutico Bergamo
As of April 7, 2011, Laboratorio Quimico Farmaceutico Bergamo Ltda was acquired by Amgen Inc.
Amgen and Daiichi Sankyo
In July 2016, Amgen and Daiichi Sankyo announced the execution of an exclusive agreement to commercialize nine biosimilars in Japan. The deal includes several biosimilars in late stage development, including biosimilars of adalimumab, bevacizumab and trastuzumab. Under the terms of the agreement, Amgen will remain responsible for the development and manufacturing of the biosimilars. Daiichi Sankyo will file for marketing approval and be responsible for distribution and commercialization in Japan, while Amgen will have a limited right to co-promote the products.
Amgen will retain all additional distribution and commercialization rights for the biosimilar programs outside of Japan. Specific financial terms of the agreement were not disclosed.
Partners: Daiichi Sankyo Co., Ltd.
Additional information available to subscribers only: